Objective: Rising COVID-19 mortality and morbidity numbers have compelled researchers and clinicians to indulge deeper into the detailed pathophysiology and potentially fatal mechanisms that could lead to preventable deaths. This paper aims to summarize and review existing research about coagulation disorders induced by COVID-19.
Design: We reviewed papers about recorded coagulation disorders induced by COVID-19, namely disseminated intravascular coagulation (DIC), thrombotic microangiopathy, and pulmonary intravascular coagulation (PIC). We also reviewed possible prophylactic and curing anticoagulation methods to counter these coagulopathies.
Results: COVID-19 induces coagulation disorders potentially fatal to patients. Therefore, prophylactic measures and testing must be done to stop the progression as early as possible. Administration of anticoagulants is also advisable in patients with a high risk of COVID-19-induced coagulopathies.
Conclusion: D-dimer is an important coagulation parameter to assess prognosis. Management of coagulation disorder and DIC on SARS-CoV-2 infection should be adjusted to clinical characteristics and hematologic evaluation. While the world is combating the pandemic, high-quality research studying pathophysiology, hematologic markers, and management strategies is essential to increase insight into COVID-19.
Key words: COVID-19, coagulopathy, disseminated intravascular coagulation, anticoagulant
|
